News Trump pledges drug price cuts – and action on 'pill penalty' A Trump executive order aimed at lowering drug prices includes a plan to do away with what industry claims is a flaw in the Inflation Reduction Act.
Sales & Marketing Executing established pharma brand strategy: Key considerati... As blockbuster drug patents edge closer to expiry, pharma companies must rethink how they invest in, support, and scale established brands
News Pharma in a spin as it tries to gauge Trump tariffs impact Pharmaceuticals are exempt from the tariffs revealed by President Donald Trump, for now, but the industry is bracing for what may come next.
News Pharma urges NHS to put medicines at heart of 10-year plan The UK pharma industry has warned that declining access to new medicines in England will undermine the government's efforts to rebuild the NHS.
News Santhera's DMD drug poised for wider rollout in Germany Santhera has agreed pricing and reimbursement for its Duchenne muscular dystrophy drug Agamree with German health funds representing 90% of patients.
Market Access NICE contribution to the cost per QALY threshold debate? Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their c
News 23andMe fined £2.31m over UK users' genetic data breach Genetic testing company 23andMe is facing a hefty fine from the UK's data protection watchdog for failing to protect its customers' data.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face